8-K: Windtree Therapeutics Faces Nasdaq Delisting Threat Over Sub-$1.00 Share Price

Windtree Therapeutics, Inc. has received a deficiency letter from Nasdaq for failing to meet the minimum bid price requirement, potentially leading to delisting.

Summary

• Windtree Therapeutics, Inc. (WINT) received a deficiency letter from the Nasdaq Listing Qualifications Department on June 18, 2025.
• The letter notified the Company that its common stock's closing bid price has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• Unlike typical situations, the Company is not eligible for the standard 180-calendar day compliance period.
• This ineligibility is due to being subject to a Discretionary Panel Monitor until March 20, 2026, and having effected two reverse stock splits with a cumulative ratio of more than 250 shares to one over the prior two-year period.
• The Company must request a hearing before a Hearings Panel by June 25, 2025, to avoid immediate suspension/delisting.
• Windtree Therapeutics intends to timely request this hearing, which will automatically stay any suspension or delisting action pending the hearing and any potential extension.
• There is no assurance that the Panel will grant an additional extension period or that the Company will ultimately regain compliance.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the immediate threat of delisting from Nasdaq, the ineligibility for standard compliance periods, and the uncertainty surrounding the outcome of the Panel hearing. This indicates significant operational and financial distress.

Negatives

• The Company's common stock has traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq listing rules.
• Windtree Therapeutics is not eligible for the standard 180-day compliance period due to prior reverse stock splits and a Discretionary Panel Monitor status.
• Failure to regain compliance could lead to the suspension or delisting of the Company's common stock from The Nasdaq Capital Market.
• There is no assurance that the Nasdaq Hearings Panel will grant an additional extension period or that the Company will ultimately regain compliance.

Risks

• Risk of delisting from The Nasdaq Capital Market if the Company fails to regain compliance with the minimum bid price requirement.
• Risk that the Nasdaq Hearings Panel may not grant an additional extension period following the hearing.
• Risk that the Company may not ultimately regain compliance with all applicable Nasdaq listing requirements, even if an extension is granted.

Future Outlook

Windtree Therapeutics intends to timely request a hearing before the Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action. However, there is no assurance that the Panel will grant an additional extension period or that the Company will ultimately regain compliance with Nasdaq's listing requirements.

Management Comments

• "The Company intends to timely request a hearing before the Panel."

Industry Context

This announcement highlights the ongoing challenges faced by smaller biotechnology or pharmaceutical companies, like Windtree Therapeutics, in maintaining compliance with major exchange listing standards, particularly the minimum bid price requirement. Such issues are common for companies undergoing clinical development or facing market capitalization pressures, and often follow periods of significant share price decline or reverse stock splits aimed at maintaining listing.

Stakeholder Impact

• Shareholders face significant risk of value erosion and reduced liquidity if the stock is delisted from Nasdaq.
• Employees may face uncertainty regarding the Company's future and potential operational changes if delisting occurs.
• Creditors may view the Company as a higher risk due to potential delisting and associated financial instability.

Next Steps

• Windtree Therapeutics must request a hearing before the Nasdaq Hearings Panel by June 25, 2025.
• The Nasdaq Hearings Panel will review the Company's case and determine whether to grant an additional extension period for compliance.
• The Company will need to demonstrate compliance with the minimum bid price requirement or other applicable listing rules to avoid delisting.

Key Dates

Recommendation

Keywords

Nasdaq delisting, minimum bid price, Nasdaq compliance, reverse stock split, deficiency letter, stock market listing, WINT, Windtree Therapeutics